Меню
Идёт набор NCT07228312

A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms

Наблюдательное Intracranial Aneurysm

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Intracranial Aneurysm. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

A Multicenter, Prospective, Single-Arm Observational Study to Evaluate the Safety and Effectiveness of the Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms

Обзор

The purpose of this study is to assess how safe choydar flow-directed mesh stent is and how well it works in the treatment of unruptured intracranial aneurysms (a condition in which a bulging blood vessel in the brain can burst and cause bleeding) in a real-world setting.

Первичные конечные точки

  • Complete Aneurysm Occlusion Rate at 12 Months Post-Procedure (Raymond-Roy Class I) [Срок оценки: At 12 months follow-up post-procedure]
  • Adequate Aneurysm Occlusion Rate at 12-month Follow-up Post-Procedure (Raymond-Roy Classes I and II) [Срок оценки: At 12 months follow-up post-procedure]
  • Percentage of Participants with Immediate Technical Success Rate of Procedure [Срок оценки: At Day 0 (Day of procedure)]
  • Re-treatment Rate of Target Aneurysm at 12-Month Follow-up Post-Procedure [Срок оценки: At 12 months follow-up post-procedure]
  • Percentage of Participants with Modified Rankin Scale (mRS) Score of 0-2 at 12 Months Post-Procedure [Срок оценки: At 12 months follow-up post-procedure]
  • Number of Participants with Major Ischemic/Hemorrhagic Events and/or Death During Perioperative Period [Срок оценки: Perioperative]
  • Number of Participants with Major Ischemic/Hemorrhagic Events and/or Death During 12-Month Follow-up [Срок оценки: At 12 months follow-up post-procedure]
  • Number of Participants with Severe in-Stent Stenosis (Greater Than [>] 50%) During 12-Month Follow-up [Срок оценки: At 12 months follow-up post-procedure]
  • Rupture Rate of Target Aneurysm During 12-Month Follow-Up Post-Procedure [Срок оценки: At 12 months follow-up post-procedure]

Критерии участия

Критерии включения

Participants meeting all the following inclusion criteria will be included:

Preoperative inclusion criteria:

  • Presence of unruptured aneurysms in the internal carotid artery (from the petrous segment to the distal end) or vertebral artery identified by digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA) prior to surgery, wide-neck (neck width greater than or equal to \[>=\] 4 millimeters \[mm\] or dome-to-neck ratio less than \[<\] 2) saccular or fusiform aneurysms, and the parent artery diameter must be >= 2.0 mm and less than or equal to \[<=\] 6.0 mm
  • Participants and/or their authorized representatives understand the purpose of the study, and are willing to voluntarily participate in the study and sign the informed consent form (ICF)
  • Prior to enrollment, a clinical decision has already been made to use the choydar flow-directed mesh stent
  • Participants who are willing and able to return for all follow-up visits as required by the study protocol

Intraoperative inclusion criteria:

\- Presence of unruptured aneurysms in the internal carotid artery (from the petrous segment to the distal end) or vertebral artery identified by DSA during the procedure, wide-neck (neck width >= 4 mm or dome-to-neck ratio <2) saccular or fusiform aneurysms, and the parent artery diameter must be >= 2.0 mm and <= 6.0 mm

Критерии исключения

Participants meeting any of the following exclusion criteria will be excluded:

  • Participants with anatomy are unsuitable for flow diverter passage or placement or lesions unsuitable for flow diverter delivery and deployment (for example, the lesion vessel is excessively tortuous or tiny, the flow diverter cannot reach the lesion site, stenosis exists in the target vessel of recurrent aneurysm, or the flow diverter is not completely deployed)
  • Participants who are allergic to contrast media
  • Participants who are allergic to nickel-titanium alloy or platinum-tungsten alloy
  • Participants who are contraindicated for antiplatelet and/or anticoagulant therapy
  • Participants with active bacterial infections
  • Participants who are confirmed positive pregnancy (for example, via test or oral communication) according to the site-specific standard of care
  • Participants who are currently participating in an investigational (drug, device, etc.) clinical study that may confound the study endpoints (excluding observational, natural history, and/or epidemiological studies that do not require interventions)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Китай · 8 центров
  • Chenzhou No.1 People's Hospital — Chenzhou
  • Guangdong Provincial People's Hospital — Гуанчжоу
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School — Нанкин
  • The First Affiliated Hospital of Nanjing Medical University — Нанкин
  • Nanyang Central Hospital — Nanyang
  • Shanxi Provincial People's Hospital — Taiyuan
  • The First Affiliated Hospital of Wannan Medical College — Wuhu
  • The First Affiliated Hospital of Zhengzhou University — Чжэнчжоу

Идентификаторы

NCT: NCT07228312 · CNV202507

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗